Subscribe for Free (RSS + E-mail)

RSS + E-mail

XSITE 2013 →
Featured▾
- Boston Angel Investors →
Xconomy San Diego
Xperience
Tech + Life▾
- View More in Xperience ›
Our
Cities▾
Tech
Channels ▾
Meet the
Xconomists ▾
Our
Events ▾

Arena Turns In FDA Application

Luke Timmerman12/22/09

Share and Comment

1 Comment Order a Reprint E-mail this Story

San Diego-based Arena Pharmaceuticals (NASDAQ: ARNA) said today it has filed its application to the FDA for clearance to start marketing lorcaserin for weight loss. The application includes information on 18 clinical trials that enrolled almost 8,600 patients, including the pivotal trials known as Bloom and Blossom. The company had forecasted previously it would complete the application by the end of 2009.

Luke Timmerman is the National Biotech Editor of Xconomy. E-mail him at ltimmerman@xconomy.com Follow @

Share or Leave a Comment

Reprints E-mail +1 Twitter LinkedIn Facebook Hacker News Comment

Related Posts

http://www.tesofensine-information.com/lorcaserin.html Lorcaserin

I have been reading that Lorcaserin is similar to fenfluramine but has not shown any of the heart value problems that fenfluramine had. It also looks like the lesser of the side effects of some of the newer obesity meds on the horizen. What about doctors prescribing Lorcaserin with Phentermine. Have there been any studies on that?